Navigation Links
Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time

Researchers from the department of urology in a hospital in Switzerland who investigated whether chemotherapeutic response to hormone-refractory prostate cancer could be measured via changes in prostate-specific antigen (PSA) found that prostate cancer doubling time may be an auxiliary marker of response to chemotherapy// in patients with hormone refractory prostate cancer.

The study was carried out with forty men who had hormone refractory prostate cancer and bi-dimensionally measurable metastases in the lymph nodes or visceral organs. The investigators calculated PSA doubling time among the patients who had a rising PSA during chemotherapy. Patients' objective best response for any of the chemotherapeutic regimens they were taking was partial remission in 6 patients (15%), stable disease in 13 (32%) and progressive disease in 21 (53%). PSA remained stable or decreased in 4 of the 6 patients who experienced a partial remission (67%), in 7 of the 13 who had stable disease (54%) and in only 4 of the 21 who had progressive disease (19%). There was a significant association between PSA and objective response. The pateints' median PSA doubling time was also studied. Among those patients who had a rising PSA, it was 238 days in patients who experienced a partial response, 224 days in those with stable disease and 113 days in patients with progressive disease.

The researchers concluded that this study indicated that PSA doubling time could be used as an auxiliary endpoint for the evaluation of response to chemotherapy in patients with hormone refractory prostate cancer and therefore could indirectly be used to assess response to chemotherapy in patients with bone metastases.


'"/>




Page: 1

Related medicine news :

1. Increasing Insulin Response In Type 2 Diabetics With New Protein Mixture
2. Reflecting On Personal Values Can Lower Stress Responses
3. Chromosome Ends Trigger DNA Damage Response For Telomere Protection
4. Good Response from Pregnant Women in Delhi for Free ART Therapy
5. Immune Response Of Human Beings Can Be Re-energized
6. Inhospitable Response Curtail Growth Of Specialty Hospitals: United States
7. Placing a Finger on Responses to Placebo Types
8. Women Portray Stronger Immune Response As Compared to Men, Study Suggests
9. WHO Commends Indias Bird Flu Response
10. Genes And Environmental Factors Determine Stress Response
11. Immune Response To Flu Shots Influenced By Bereavement And Marital Status
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic Trainers from ... Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, evidence based ... Trainers are acknowledged by their peers with accolades and highly prestigious awards. This ...
(Date:9/20/2017)... ... 2017 , ... Medicare doesn’t have the authority to negotiate ... their prescription drugs, according to a new comparison of drug plans by ... there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare policy ...
(Date:9/20/2017)... ... 20, 2017 , ... “Finn Mouseson”: follows the exciting story of a mouse ... mouse sets out on a journey that will show that friends are to be ... newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree in ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe for ... of published author, Brooks Rathell. , “We typically hear about the favor of God. ... favor of God. Not only does it exist, but it is meant for you. ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a ... leader, Denise Flannery, to its strategic advisory and client development team. , ... work with clients across different industries to develop and implement market-justified strategies, modernize ...
Breaking Medicine News(10 mins):
(Date:9/1/2017)... N.J. , Sept. 1, 2017  Bayer will present ... the European Society for Medical Oncology (ESMO) 2017 Congress, September ... presented will include new preclinical and clinical data on Bayer,s ... two earlier pipeline projects. ... the best minds in cancer research at ESMO," said ...
(Date:8/29/2017)... -- ivWatch, LLC, the leading provider of continuous monitoring devices for ... awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven ... ... early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch based ...
(Date:8/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the ... in New York . John Greisch ... present at 11:05 a.m. Eastern Time. The ... A recorded replay will be available one hour after the ... About Hill-Rom Holdings, Inc. ...
Breaking Medicine Technology: